| Literature DB >> 35262728 |
Jiarong Zhou1, Yukiko Miyamoto2, Sozaburo Ihara2,3, Ashley V Kroll1, Noelle Nieskens2, Vivien N Tran2, Elaine M Hanson2, Ronnie H Fang1, Liangfang Zhang1, Lars Eckmann2.
Abstract
The protozoan pathogen Giardia lamblia is an important worldwide cause of diarrheal disease and malabsorption. Infection is managed with antimicrobials, although drug resistance and treatment failures are a clinical challenge. Prior infection provides significant protection, yet a human vaccine has not been realized. Individual antigens can elicit partial protection in experimental models, but protection is weaker than after prior infection. Here, we developed a multivalent nanovaccine by coating membranes derived from the parasite onto uniform and stable polymeric nanoparticles loaded with a mucosal adjuvant. Intranasal immunization with the nanovaccine induced adaptive immunity and effectively protected mice from G. lamblia infection.Entities:
Keywords: biomimetic nanoparticle; giardiasis; intestinal mucosa; multivalent vaccine; nanovaccine; protozoa
Mesh:
Substances:
Year: 2022 PMID: 35262728 PMCID: PMC9400425 DOI: 10.1093/infdis/jiac074
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 7.759